웨이브 라이프 사이언시스

Wave Life Sciences Ltd., a clinical-stage biotechnology company, focuses on unlocking the ribonucleic acid (RNA) medicines to transform human health. Its PRISM platform combines various modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers) provides with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The company's pipeline focuses various programs, including WVE-007, for obesity; WVE-006 for alpha-1 antitrypsin deficiency; and WVE-008 for PNPLA3 I148M liver disease. It also includes clinical programs in Duchenne muscular dystrophy and Huntington's disease, as well as several preclinical programs utilizing its versatile RNA medicines platform. The company has collaboration and license agreement with GlaxoSmithKline Intellectual Property (No. 3) for the research, development, and commercialization of oligonucleotide therapeutics. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.